Contributions to the literature

  • Member States’ health systems determine WHO guideline uptake; weaker health systems continue to have low uptake and use of WHO guidelines.

  • The challenges for WHO guideline uptake reflect the health systems’ (in)ability to allocate, implement and monitor adherence to the guidelines. Historically this is beyond the remit of WHO, but Member States could benefit from WHO implementation guidance on requirements and needs for successful deployment of normative and standard-setting products.

  • Robust feedback mechanisms between WHO and Member States help to optimize WHO guideline uptake in Member States and contribute to the guideline development process.

Background

WHO has a long tradition of supporting the Member States in developing national health policies, strategies and plans through country-level technical cooperation, facilitation of national policy dialogue and inter-country exchange, as well as through its normative work, including the provision of guidelines [1]. WHO defines a guideline as any document developed by WHO containing recommendations for clinical practice or public health policy. These guidelines outline recommendations for end-users regarding what can or should be done in specific situations to achieve the best health outcomes possible. Guidelines are the fundamental means by which the organization fulfils its technical leadership role in health [2].

Low- and middle-income countries (LMICs) often lack resources and/or skills to develop local guidelines and instead rely on guidelines developed by WHO and other international organizations [3]. Constraints in guideline development in LMICs include methodological problems and inadequate resources [4, 5]. Scholars have critically argued that the adoption of guidelines in LMICs, in merely attempting to emulate “clinical guidelines developed in rich countries, risks placing unnecessary strains on their health services” [6]. WHO plays a critical role in addressing the need for evidence-informed guidance for the Member States, particularly LMICs. For example, WHO guidelines provided a valuable reference for establishing new national regulatory requirements or updating existing ones and promoting convergence at the global level to enable regulatory cooperation for biotherapeutics among the Member States [7].

WHO’s Thirteenth General Programme of Work (GPW13) also prioritizes strengthening its normative functional role and uptake of normative and standard-setting products (NSPs) inclusive of guidelines at the country level [8]. As such, WHO policy-makers and guideline developers seek to understand the extent of uptake and how the guidelines are integrated into the policy and practice in LMICs, where the maximum use of WHO guidelines is expected. However, the literature reveals limited evidence evaluating the uptake, use and impact of WHO guidelines [3, 9,10,11]. WHO has also echoed a limited understanding of the uptake and use of NSPs by the Member States, and aimed to understand the barriers to uptake and use and determinants of success of WHO’s NSPs at the policy and practice levels in LMICs [12].

Since 2007, WHO’s Guidelines Review Committee (WHO GRC) has engaged in defining the standards and methods for all guidelines that are funded, developed and issued by WHO, and follows rigorous methods of development to ensure its recommendations are evidence-based [13]. To optimize uptake and use of WHO’s GRC-approved guidelines, WHO commissioned a review of the literature to contribute to what is known about the uptake and use of WHO guidelines in LMICs. The review findings were intended to inform WHO about existing evidence around barriers to guideline uptake and to support WHO’s Department of Quality Assurance, Norms and Standards activities (QNS), particularly in strengthening the framework for monitoring, evaluation and learning on the uptake and use of WHO norms and standards in LMICs. Accordingly, we conducted a scoping review to summarize evidence on the barriers to uptake of WHO’s clinical and public health guidelines at the policy and practice levels amongst LMICs, thereby contributing to WHO’s understanding of its guideline uptake.

Methods

A scoping review is defined as a type of research synthesis that aims to “map the literature on a particular topic or research area and provide an opportunity to identify key concepts; gaps in the research; and types and sources of evidence to inform practice, policymaking, and research” [14, 15]. We conducted a scoping review between May and June 2021, to identify and synthesize the evidence around barriers to uptake of WHO GRC-approved guidelines in LMICs. Due to significant heterogeneity in the aspects of guideline topics, implementation interventions, study design and outcomes across the included studies, the project advisory committee determined that using a meta-analysis may not have been worthwhile for pooling the quantitative data. Further, the use of a narrative synthesis was recommended as more appropriate for presenting the themes and subthemes in the scoping review.

Search strategy

The search strategy aimed to identify published articles that evaluated WHO guideline uptake in LMICs. We searched five electronic databases including CINAHL, the Cochrane Library, PubMed, Embase and Scopus. We also searched Google Scholar as a supplementary source. The search was limited to studies published between January 2007 (inception of WHO GRC) and December 2020. We also reached out to the WHO departments and experts in implementation science to retrieve relevant published or grey literature. The search strategy for the scoping review, including a detailed list of search terms, was developed and finalized in consultation with the project advisory committee members and the WHO team. The detailed search strategies for each database are included in Additional file 1.

Study selection criteria

Studies were included if they evaluated country-specific adaptation/adoption/contextualization, implementation and uptake/use of WHO GRC-approved clinical practice and public health guidelines within LMICs. Because of the limited time frame for this review, the selection of records was limited to studies reporting on guidelines for specific health conditions including nutrition; maternal, newborn and child health (MNCH); communicable diseases; noncommunicable diseases (NCDs) and neglected tropical diseases. These health conditions were selected in consultation with the project advisory committee based on the disease burden in LMICs. Further, as health conditions were broad, the project advisory committee advised the project team to limit their review to specific diseases. Accordingly, for communicable diseases, we have included only the big three infectious diseases—HIV, tuberculosis (TB) and malaria—and for neglected tropical diseases, which comprise a diverse group of 20 tropical infections, we have included only filariasis and schistosomiasis. While there was no restriction on study design for the inclusion of studies in the review, we excluded records that were not published in the English language and those that were purely descriptive, as well as those that did not formally evaluate WHO guidelines or their components. For our selection criteria, “purely descriptive” studies are studies that describe or present the implementation process of and/or experience with guidelines without any assessments or evaluations through quantitative, qualitative or mixed approaches.

WHO guideline and descriptor terms

Scholars have noted that the titles of WHO guidelines often include a variety of descriptor terms other than “guidelines” itself [16], rendering it difficult to identify WHO guidelines. A recent study on WHO guidelines reported considerable variation in descriptor terms used for the WHO documents, including guideline(s), recommendation(s), guidance, policy statements and a variety of other terms (manual, rapid advice, handbook, statement, guide, toolkit, technical paper) [16]. In order to develop our screening criteria and to determine whether the descriptor reported in the articles qualified as a WHO guideline, we obtained from the WHO QNS team a comprehensive list of GRC-approved WHO guidelines recorded in the WHO Institutional Repository for Information Sharing (IRIS) database to identify all the terms used to define WHO guidelines. The data retrieved from the IRIS database included 439 WHO GRC-approved guidelines published between 2007 and 2020, 62% of which (n = 273) were in English. These guidelines have used varied descriptor terms such as guidelines (n = 151), recommendation/s (n = 5), policy guidance (n = 8), policy statement (n = 6), guidance (n = 5) and others (n = 98). Our review team screened and categorized these guidelines as per the preselected health conditions considered for this review (Table 1). The final list guided our screening criteria.

Table 1 The list of health conditions for the 273 English-language guidelines
Full size table

Eligibility assessment and data extraction

All records identified through searches were uploaded to a proprietary review management software programme (Covidence), and duplicate references were identified and subsequently removed. Four authors (KS, KSR, QW, YZ) piloted the study selection process on a sample of records (n = 20) based on the predefined inclusion/exclusion criteria, and inter-rater agreement was assessed. When sufficient agreement was reached, the titles and abstracts for all the records were independently screened by two authors to identify eligible articles. Disagreements at this stage were resolved through discussion among the four reviewers. Full-text records were retrieved and reviewed for inclusion by a single author and verified by a second author. The review team followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews (PRISMA-ScR) for reporting decisions for inclusion/exclusion and reporting of review items [17,18,19,20]. Once inclusion was established, data were extracted for each study using a pre-piloted data extraction form. The data extraction items included the author(s), publication year, study location (name of LMICs), the WHO guideline(s) of interest, the condition(s)/topics, aims/objectives of the study, study design, barriers, facilitators/enablers, implementation interventions/suggestions/recommendations and implementation frameworks. Four authors (KS, KSR, QW, YZ) separately extracted the above items from the included studies, and another two senior authors (KS, KSR) further randomly checked the extracted data for imprecision. Based on the finalized data extraction from the included studies, focusing on our research questions, we categorized the themes and related subthemes and organized their relationships through multiple group discussions. We stopped adding new themes and subthemes upon data saturation [21, 22].

Results

Forty-eight studies were identified as eligible for inclusion following full-text assessment (n = 48/7159) (Fig. 1). Two records were further identified as eligible for inclusion following reference list screening of the included records.

Fig. 1
figure 1

Scoping review study flow diagram

Full size image

The detailed characteristics of the included studies and findings are presented in Table 2. The review findings reveal key barriers for uptake and use of WHO GRC guidelines and are thematically categorized as (1) lack of national legislation, regulations and policy coherence, (2) inadequate experience, expertise and training of healthcare providers for guideline uptake, (3) funding limitations for guideline uptake and use, and (4) inadequate healthcare infrastructure for guideline compliance. For each thematic area, we present key examples of reported barriers to WHO GRC guideline uptake.

Table 2 Studies on WHO guideline uptake and use included in the review
Full size table

Lack of national legislation, regulation and policy coherence

Public health legislation aims to promote or protect public health [23]. Our findings suggest that national public health legislation and regulations are pivotal to WHO guideline uptake and use in LMICs and a lack therein limits uptake. For example, in the context of communicable diseases, integrated vector management (IVM) is a vital component for controlling neglected tropical diseases and vector-borne diseases. In 2008, WHO issued a position statement supporting IVM consistent with the global strategic framework for IVM. However, one of the key reasons cited for the slow uptake of IVM was “the lack of legislative activities”, as implementation strategies for the IVM framework extend beyond the health sector. Therefore, intersectoral collaboration and establishment of regulatory and legislative control for public health and pesticide management, among others, were found critical for effective IVM programme implementation in malaria-endemic countries [24].

For NCDs, in response to the escalating burden of NCDs worldwide, the World Health Assembly (WHA) endorsed the WHO Global NCD Action Plan 2013–2020, which provides several evidence-based policy recommendations as “best buys” for NCD prevention and control. The Member States have adopted the NCD action plan; however, most best buy interventions were underutilized globally [25]. For example, the implementation of the WHO policy recommendations remained low in LMICs of Africa due to “a lack of legislation and regulations for NCD control” [26]. Scholars have noted that legislation and regulatory frameworks are critical for NCD prevention [27, 28]. The taxation on sugar-sweetened beverages with nutrition-sensitive agricultural policies can potentially improve overall health and nutrition in Africa [27]. However, lack of political will, legislative restrictions and competing government priorities were identified as major barriers to policy coherence in Africa and elsewhere [27, 29].

Another recent review noted that although multisectoral collaboration and coordination were proposed at the policy level to tackle NCDs in India, gaps remained in the implementation of such policies. The implementation gaps were reported at two levels: (1) at the intervention level, which included promoting physical activity in schools and society and restricting marketing of and access to food products high in salt, sugar or unhealthy fats, and (2) at the legislative level, which included clean indoor air legislation, tobacco advertising ban and raising the tax on tobacco products [28]. Similarly, another review found that “regulatory frameworks” were essential for public health interventions targeting nutrition [30]. The main types of regulatory frameworks include food safety and food fortification regulatory frameworks, among others, established by various international and national authorities. For example, the European Food Safety Authority for member countries of the European Union, the Food and Drug Administration in the United States, and the Health Products and Food Branch of Health Canada set the framework for the fortification of foods, along with the Regional Commission on Micronutrients and Fortified Foods in Central America and the National Commission on Micronutrients in Costa Rica, among others.

For MNCH, WHO recommends improving access to key maternal and newborn health interventions through task-shifting guidelines [31]. For the effective uptake and use of these recommendations, the legal protections and regulatory framework were found essential [32]. WHO guidelines also recommend preventing early pregnancy and poor reproductive health outcomes among adolescents in LMICs. However, guideline uptake in Ethiopia, for example, was constrained by “lack of supporting laws and legislation along with other barriers” [33]. Studies have reported that government policies prohibit the implementation of recommendations for postpartum haemorrhage (PPH) guidelines. For example, the administration of misoprostol by community healthcare workers was not supported by the policy in Uganda, despite studies conducted in Uganda demonstrating the safety and effectiveness of this approach under the supervision of midwives [34]. A similar lack of legal frameworks was found for the uptake of female genital mutilation (FGM) guidelines in most countries wherein FGM is practised [35].

Inadequate experience, expertise, training and attitudes of healthcare providers

Healthcare providers play an invaluable role in healthcare delivery. Hence, the capacity-building of healthcare providers is essential in a health system. Advancement of knowledge and skills among practitioners is an important aspect of capacity-building [36]. WHO defines capacity-building as “the development of knowledge, skills, commitment, structures, systems and leadership to enable effective health promotion…[with] actions to improve health at three levels: the advancement of knowledge and skills among practitioners; the expansion of support and infrastructure for health promotion in organizations; and, the development of cohesiveness and partnerships for health in communities” [37].

For communicable diseases, studies found that the strength of recommendation and evidence quality determined national policy adoption of WHO HIV guidelines in LMICs in South-East Asia and Africa [38]. In contrast, a comparative analysis of HIV testing and treatment services in six sub-Saharan African countries argued that WHO did not provide explicit guidance on HIV testing and treatment services. As a result, countries had to move beyond WHO standards to formulate national HIV treatment policies. While there was insufficient guidance from WHO, the countries stipulated the need for periodic refresher training for healthcare providers on HIV prevention and treatment [39]. Other studies also reported that despite concerted efforts to provide treatment consistent with WHO guidelines, lack of health information and data integration have constrained the uptake and use of WHO’s guidelines for the prevention of mother-to-child transmission (PMTCT) of HIV in most LMICs [40, 41]. WHO and UNICEF [United Nations Children’s Fund] recommend that HIV-positive women avoid all breastfeeding only if replacement feeding is acceptable, feasible, affordable, sustainable and safe. However, the recommendations were not implemented effectively within operational settings in many African countries due to the lack of standardized health messaging for mothers to adopt the best practices, leading to inappropriate infant feeding choices and consequent lower infant HIV-free survival [42,43,44].

For MNCH, in 2018, WHO called for global action towards the elimination of cervical cancer, with a key strategy, among others, to screen 70% of women between the ages of 35 and 45 years. A study suggests well-organized screening programmes in high-income countries, but due to the lack of extensively experienced clinicians, LMICs did not achieve similar progress [45]. In 2011, WHO recommended misoprostol use to manage and prevent PPH in settings where oxytocin is not available and included misoprostol in its essential medicines list (EML) model. However, fear and confusion among policy-makers, programme managers and healthcare providers, lack of awareness about existing policy, and lack of integration of misoprostol in basic health service packages have been cited as substantial barriers to successful implementation of misoprostol administration in developing countries [46]. A review also highlighted that the research evidence does not support misoprostol use in home and community settings in LMICs for PPH prevention and indicated that WHO should rethink its decision to include misoprostol on the EML [47]. Nevertheless, the review suggested that government and policy-makers should focus on strengthening the health system and training birth attendants to prevent PPH in LMICs.

Though providers perceive PPH guidelines as useful, lack of guideline awareness, poor access to guidelines, prioritizing experience over evidence and incorrect clinical practice were key barriers to PPH guideline implementation in Kosovo [48]. In another example, descriptions of the guidelines were superficial and there were discrepancies as to which ones were used in clinical practice; limited access to guidelines (insufficient copies) at healthcare facilities, adherence to midwifery school-based knowledge rather than guidelines as best practices, and lack of knowledge about the rationale for using the guidelines (e.g. use of oxytocin) were cited [49]. In addition, lack of up-to-date guidance on recommended practices was highlighted as a challenge, particularly around the use of misoprostol for prevention of PPH in health facility settings in Uganda [34].

WHO recommends antenatal care (ANC) for a positive pregnancy experience for women, regardless of the income status of the country. However, lack of access to external training programmes was reported as a key barrier to compliance with ANC and PPH guidelines in LMICs [49,50,51]. In 2009, WHO and UNICEF issued a joint statement recommending home visits by community-based agents as a strategy to improve newborn survival. Evaluation studies conducted in LMICs cited poor health worker attitudes as barriers to uptake of the strategy [52] and optimal use of guidelines at the facility level [53].

Funding limitations for guideline uptake and implementation

Adequate funding is essential for fulfilling the “ten essential public health operations” emphasized in WHO’s essential public health services framework [54]. However, LMICs continue to have limited public health funding and spending and rely on bilateral and multilateral assistance and other donor support. Our review suggests that the uptake and use of WHO guidelines in LMICs is significantly constrained by limited domestic public health funding and investments.

For communicable diseases, indoor residual spraying (IRS) is a proven effective malaria vector intervention if correctly implemented using WHO-recommended insecticides. Implementation of IRS programmes in malaria-endemic countries has often been constrained by funding limitations. For example, IRS programme implementation in Malawi was found to be uncertain due to limited funding, cost of alternative insecticides and technical resource challenges experienced in the country [55].

The 2013 WHO guidelines for antiretroviral therapy (ART) recommend expanding eligibility to include several new groups of people living with HIV, notably all HIV-infected adults with CD4þ T-cell counts between 350 and 500 cells/ml, all pregnant women and serodiscordant couples regardless of CD4þ T-cell count, and all HIV-positive children up to the age of 5 years. These guidelines were expected to double the number of people living with HIV/AIDS (PLHIV) on treatment, but several challenges limited its uptake in many countries [34, 53, 56]. The most common barriers to the timely implementation of new ART initiation guidelines were economic constraints for the procurement of drugs [57].

In 2015, WHO provided guidelines recommending that any person at substantial risk of HIV be offered oral pre-exposure prophylaxis (PrEP) containing tenofovir disoproxil fumarate (TDF) as an additional prevention choice. Further, in 2017, PrEP medicines were listed in WHO’s EML, including TDF/emtricitabine (FTC) and TDF in combination with lamivudine (3TC). By the end of 2018, at least 40 countries (20.6%) were anticipated to have adopted WHO’s oral PrEP recommendation. However, policy uptake and programmatic coverage of PrEP services were constrained by the underlying cost of PrEP services in LMICs [58]. Since 2015, WHO has also recommended a commercially available lateral-flow urine lipoarabinomannan (LAM) test (Alere-LAM) to assist in diagnosing TB in severely ill people living with HIV; however, the most commonly cited constraint to adoption and implementation of LAM was budget limitations [59].

For NCDs, WHO recommends virtually eliminating trans fat from the global food supply. LMICs such as India face several challenges, requiring a multisectoral food chain approach to remove trans fats from the food supply. Empirical evidence suggests that economic incentives for manufacturing foods using healthier oils are imperative in India and elsewhere [60]. In 2012, WHO set the 25 × 25 goal to achieve a 25% reduction in the number of premature deaths (occurring before 70 years of age) due to NCD by 2025. A global action plan followed this with a target of 80% availability and affordability of essential medicines for treatment and secondary prevention of cardiovascular disease (CVD) and other NCDs, and at least 50% of eligible people to receive drug therapy and counselling (including glycaemic control) to prevent heart attacks and strokes. A study reported a mean availability of essential medicines for CVD of 33%, much lower than the recommendation, and the available medicines were largely unaffordable, pointing towards the need for substantial investments in the LMICs [61].

For MNCH, in 2007, the 60th WHA passed a resolution entitled “Better medicines for children”. Subsequently, WHO recommended the inclusion of child-appropriate dosage formulations in the EMLs of Member States. However, LMICs have either delayed or not included these recommendations in their national EML. The key barriers included a lack of resources that hindered the formal transfer of the policy from the global to the local level [62]. A qualitative study conducted in Ethiopia and Senegal also found that while WHO’s evidence-based family planning guidance and tools were trustworthy, compliance was constrained by limited resources [63].

Inadequate healthcare infrastructure for guideline compliance

Public health infrastructure provides the necessary foundation for undertaking the basic responsibilities of public health, which have been defined as the 10 essential public health operations [54]. Every public health programme requires health professionals who are competent in cross-cutting and technical skills, up-to-date information systems, and public health organizations with the capacity to assess and respond to community health needs. Public health infrastructure has been referred to as “the nerve center of the public health system” [64]. However, in most LMICs, the public health infrastructure is inadequate for prevention and treatment programmes.

For communicable diseases, the LMICs, especially sub-Saharan African countries, had suboptimal uptake of WHO ART guidelines due to inadequate health systems in those countries. The barriers reported included no operating budget to support scale-up, difficulty transporting samples, delays in commodity procurement and distribution, inadequate laboratory information systems, insufficient trained human resources dedicated for viral load testing, equipment breakdown, delay in equipment repair, inadequate laboratory and storage space to accommodate sample volume, and insufficient viral load testing results management (record keeping and use of results for patient management in healthcare facilities) [34, 65].

For TB prevention, improved access to rapid diagnostics for TB drug resistance and second-line TB treatment was recommended [66]. Based on the 2018 WHO treatment guidelines for multidrug-/rifampicin-resistant tuberculosis (MDR/RR-TB), the capacity for drug susceptibility testing was reportedly insufficient in resource-limited settings, requiring national TB programmes to strengthen their capacity to detect and manage MDR-TB in accordance with the WHO guidelines [67]. Similarly, other studies identified lack of equipment, supplies and human resources as significant barriers to optimal malaria care in Tanzania and Kenya and the PMTCT of HIV in Malawi [68,69,70].

For MNCH, in the vast majority of countries, ANC is provided free of charge. Accessibility and availability of local transport (for example, visiting a clinic in a distant location or in an unfamiliar part of town), indirect costs associated with transport to and from the clinic in resource-poor settings and the purchase of additional medicines were reported as barriers to ANC engagement in several LMICs [71]. The lack of privacy in the delivery of ANC, rigid and inflexible appointments, lack of medicine and medical equipment at clinics, poor explanation of tests and lack of continuity of care also limit the delivery of quality ANC in LMICs [50, 72, 73]. Studies also suggested the need for a smaller number of evidence-based quality indicators for quality of care in LMICs as opposed to an overwhelming number of indicators in the WHO guidelines [74, 75]. Another study found that a lack of healthcare infrastructure was a significant barrier to the WHO-recommended integrated management of neonatal and childhood illness (IMNCI) strategy compliance in Ethiopia [76].

Discussion

Public health in LMICs is complex; implementing and taking up broad-sweeping guidelines is even more complex. Our findings reveal that guideline uptake in any one WHO Member State is influenced by a multifactorial interplay of factors such as awareness of guidelines, funding, infrastructure, legislation and regulations. While most of the identified barriers can be directly attributed to challenges within the national health systems context, some barriers are associated with the WHO guidelines themselves.

Stronger health systems for guideline uptake

Health systems are expected to fulfil three main functions—healthcare delivery, fair treatment to all and meeting health expectations of the population, for which governance is vital. Health system governance is “an aggregation of normative values such as equity and transparency within the political system in which a health system functions” [77]. It involves (1) setting strategic direction and objectives; (2) making policies, laws, rules, regulations or decisions, and raising and deploying resources to accomplish the strategic goals and objectives; and (3) overseeing and making sure that the strategic goals and objectives are accomplished [78]. However, the review findings suggest that governance within the existing health systems in LMICs is weak, as is the guidance provided by WHO guidelines on governance requirements. This includes weak or absent legislation or regulations, poor appreciation of procurement and stock-out challenges, and weak follow-up at the policy and practice levels. This is further exacerbated by a lack of accountability and transparency mechanisms for guideline uptake and implementation within the Member States, particularly LMICs.

Health infrastructure challenges encompassing management and operations issues, systems and technical needs, to community resources were evident in guideline uptake for the health conditions selected in the study. For example, the review findings suggest that lack of infrastructure is a critical barrier for guideline uptake and use in ANC in LMICs [68]. These findings are consistent with the studies undertaken for mobile health (mHealth) intervention implementation in Africa [79]. Studies have found that some of the infrastructural deficits in LMICs may be improved by learning from and building on the successful response to HIV/AIDS through interactions between high-income countries and LMICs [3].

The resource constraints were evident in the evaluation studies undertaken in LMICs, particularly the clinical practice guidelines. For example, with regard to WHO ART guidelines uptake, most of the LMICs did not have a health system in place for guideline uptake and use, requiring domestic, bilateral and multilateral funding to support guideline implementation. In addition, human resources capacity gaps such as poor-quality training, lack of opportunities for skill enhancement and lack of accountability for adherence to guidelines, lack of communication/interprofessional collaboration, and ethnic/cultural differences were cited as barriers to WHO guideline uptake and use in healthcare settings [68]. These challenges reflect the national health systems’ ability to allocate, implement and monitor the guidelines, which historically is beyond WHO’s remit. Nevertheless, the evidence suggests that financial incentives and penalties encourage the uptake of healthy behaviours [80, 81] and compliance with clinical practice guidelines [82] and treatment guidelines [83]. Therefore, WHO guideline developers could potentially explore these possible opportunities for better uptake when developing the guidelines.

Weak health systems hinder the implementation of effective interventions [84]. Poor uptake of guidelines continues to be a significant challenge across health systems, particularly in conflict-hit countries [85]. Evidence suggests that women living in regions with extremely high levels of conflict had decreased odds of meeting the WHO recommendations [86]. For example, study identified several challenges in Kosovo regarding the uptake of maternal health guidelines and their contextualization for local use. The 1998–1999 conflict substantially and adversely affected the healthcare infrastructure in Kosovo, which has resulted in an inability to monitor the quality of care across the country. Furthermore, the impact on infrastructure has affected the ability for consistent access to required medications and smooth transfer of patients from rural to urban centres [87]. This demonstrates the role of stable and robust health systems as a critical determinant for guideline uptake in LMICs.

Addressing WHO guideline complexities, weaknesses and implementation guidance

Notwithstanding health systems challenges, the review findings suggest that the WHO guidelines themselves were either unclear or weak and were technically challenging. Evidence from implementation research has shown that detailed implementation plans are often necessary for local policy-makers to use WHO guidelines. Studies have also found that end-users’ adherence to and uptake of guidelines are negatively affected by guidelines without adequate implementation plans [10, 88, 89].

Further, implementation advice was often not provided, especially in terms of sustained capacity-building, which limited stakeholder engagement [90], and guidelines were often too technical and did not cater to end-user needs. The review found these limitations, for example, in PPH guidelines [34] and maternal and newborn care guidelines in health facilities [74], and this was consistent with studies that reported WHO’s confusing guidance on masks in the COVID-19 pandemic [91]. Similar to many empirical research studies on a variety of health conditions in this review, the WHO evaluation office commissioned an evaluation of the impact of the WHO publications, which also found that WHO products were often described as “too long, too technical” and needed to be tailored to different audiences [92].

Our findings also suggest that WHO guidelines were being used as a reference by Member States when developing their national guidelines. However, guideline dissemination and the monitoring and evaluation of guideline uptake were not well documented by WHO or the Member States for optimizing guideline uptake. A WHO-commissioned assessment of the contribution of WHO guidelines to improving reproductive, maternal and newborn health in the South-East Asia Region found that WHO engaged its intended audience by deploying various dissemination means (e.g. electronic, regional meetings). However, the process was not well monitored or documented regarding the distribution of emails, downloads from websites and distribution of printed copies [93]. Similarly, another review found a lack of well-documented adaptation methodologies in national HIV and/or TB guidelines and the need for a standardized and systematic framework for guideline adaptation and improved reporting of processes for guideline use [94]. Further, the WHO guidelines often do not include feedback mechanisms for compliance between WHO and Member States, significantly restricting the ability to understand, monitor and evaluate guideline uptake.

Policy implications

The WHO GPW13 focuses on Triple Billion targets to achieve measurable impacts on population health at the country level. The Triple Billion targets include one billion more people benefiting from universal health coverage, one billion more people better protected from health emergencies, and one billion more people enjoying better health and well-being. WHO’s guidance is vital in achieving the Triple Billion targets and measurable impacts on population health for the Member States. As the review findings determine the direct correlation between guideline uptake and health systems, the organization, while producing evidence-based guidelines for better health outcomes in Member States, should continue to encourage the building of stronger health systems to optimize the WHO guidelines in the Member States. Additionally, WHO should monitor and evaluate the uptake of its guidelines with either existing or new monitoring, evaluation and learning frameworks and feedback loops between WHO and Member States for optimizing WHO guideline uptake in Member States. WHO SMART (standards-based, machine-readable, adaptive, requirements-based and testable) guidelines are a comprehensive set of reusable digital health components as a way forward for optimizing guideline uptake [95].

Future research recommendations

Guideline developers should work collaboratively with guideline implementors and researchers to design and conduct evaluations of guideline implementation, especially in the LMICs, to identify additional contextually sensitive barriers and facilitators. Targeted implementation strategies could then be developed and tested in the local settings. Also, the funding organizations should focus on and encourage these evaluation and monitoring studies. As for addressing the barriers related to the WHO guidelines, researchers should focus on the impact of different formats and reporting characteristics of the guideline recommendations, and engage with guideline implementors and developers to identify the optimal formats that they could accept.

Limitations of the study

WHO maintains the Global Index Medicus (GIM) data, which provides worldwide access to biomedical and public health literature produced by and within LMICs. By not including GIM in our search strategy, the review may have missed some critical articles from the LMICs. Also, our screening criteria included literature in English only, restricting the review to articles published in the English language.

Conclusions

The challenges for WHO guideline uptake reflect the health systems’ ability to allocate, implement and monitor the guidelines. Historically this is beyond the remit of WHO, but Member States could benefit from WHO implementation guidance on requirements and needs for successful deployment of WHO’s NSPs, including the guidelines. The impact on health outcomes is derived primarily from guideline implementation; however, the extent to which guidelines are implemented in countries, and the quality of that implementation, largely remains unknown. WHO guidelines are referenced and adapted to a large extent at the country level into national policies, strategies, plans and clinical guidelines.